CLINICAL-TRIAL OF CEFOTAXIME IN PATIENTS WITH TYPHOID-FEVER
- 1 January 1985
- journal article
- research article
- Vol. 7 (4) , 448-451
Abstract
In 45 patients in whom typhoid fever was confirmed by culture of a blood sample, cefotaxime (1 g BID [twice a day]) was administered i.v. for 4 days; if defervescence did not occur by day 5, the dosage was increased to 2 g BID until defervescence, when it was reduced to 1 g BID until discharge. On average, defervescence occurred on day 7 (range, day 3-14), requiring a total dose of 31 g (range, 12-60 g) of cefotaxime. Relapse, occurring in 3 patients, was treated with co-trimoxazole. The duration of cefotaxime therapy was longer than therapy with chloramphenicol but without the risk of bone marrow depression.This publication has 5 references indexed in Scilit:
- Cefotaxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitroJournal of Antimicrobial Chemotherapy, 1978
- Activity of HR 756 against Haemophilus influenzae, Barteroides fragilis and Gram-negative rodsJournal of Antimicrobial Chemotherapy, 1978
- Typhoid Fever in the United States Associated with the 1972-1973 Epidemic in MexicoThe Journal of Infectious Diseases, 1977
- COMPARATIVE EFFICACY OF CHLORAMPHENICOL, AMPICILLIN, AND CO-TRIMOXAZOLE IN THE TREATMENT OFThe Lancet, 1976
- Chloramphenicol-Associated Blood DyscrasiasJAMA, 1967